N

    Novartis AG ADR (NVS)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $152.06
    -1.75 (-1.14%)

    Market Cap: $289.02B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    76%(31/41)
    Avg Surprise
    +2.75%
    Streak
    3 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$2.23
    Range$2.20 - $2.26
    2 analysts
    EPS Revisions
    2
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$2.13-4.6%
    60d ago$2.16-3.3%
    30d ago$2.16-3.3%
    7d ago$2.20-1.3%
    Current$2.23
    Revenue Consensus
    $14.7B
    Range$14.3B - $14.9B
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$2.36
    Range$2.17 - $2.60
    8 analysts
    Revenue Consensus
    $15.5B
    Range$13.9B - $17.7B
    20 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$2.36---
    Sep 26EST
    		-$2.23---
    Jun 26
    Reported Jul 21
    		$2.41$2.20+9.55%Beat+7.1%
    Mar 26
    Reported Apr 28
    		$1.65$1.65+0.00%Beat-31.8%
    Dec 25
    Reported Feb 4
    		$2.03$2.00+1.50%Beat-11.0%
    Sep 25
    Reported Oct 28
    		$2.25$2.31-2.60%Miss+13.6%
    Sep 25
    Reported Oct 28
    		$2.25$2.26-0.44%Miss+9.2%
    Jun 25
    Reported Jul 17
    		$2.42$2.37+2.11%Beat+22.8%
    Mar 25
    Reported Apr 29
    		$2.28$2.17+5.07%Beat+26.7%
    Dec 24
    Reported Jan 31
    		$1.98$1.76+12.50%Beat+29.4%
    Sep 24
    Reported Oct 29
    		$2.06$1.93+6.74%Beat+18.4%
    Jun 24
    Reported Jul 18
    		$1.97$1.86+5.91%Beat+7.7%
    Mar 24
    Reported Apr 23
    		$1.80$1.68+7.14%Beat+5.3%
    Dec 23
    Reported Jan 31
    		$1.53$1.66-7.83%Miss+0.7%
    Sep 23
    Reported Oct 24
    		$1.74$1.74+0.00%Beat+10.1%
    Jun 23
    Reported Jul 18
    		$1.83$1.76+3.98%Beat+17.3%
    Mar 23
    Reported Apr 25
    		$1.71$1.53+11.76%Beat+17.1%
    Dec 22
    Reported Feb 1
    		$1.52$1.43+6.29%Beat+8.6%
    Sep 22
    Reported Oct 25
    		$1.58$1.62-2.47%Miss-7.6%
    Jun 22
    Reported Jul 19
    		$1.56$1.54+1.30%Beat-6.0%
    Mar 22
    Reported Apr 26
    		$1.46$1.51-3.31%Miss-3.9%
    Dec 21
    Reported Feb 2
    		$1.40$1.41-0.71%Miss+4.5%
    Sep 21
    Reported Oct 26
    		$1.71$1.66+3.01%Beat+12.5%
    Jun 21
    Reported Jul 21
    		$1.66$1.49+11.41%Beat+22.1%
    Mar 21
    Reported Apr 27
    		$1.52$1.62-6.17%Miss-2.6%
    Dec 20
    Reported Jan 26
    		$1.34$1.39-3.60%Miss+1.5%
    Sep 20
    Reported Oct 27
    		$1.52$1.45+4.83%Beat+7.8%
    Jun 20
    Reported Jul 21
    		$1.36$1.33+2.26%Beat+1.5%
    Mar 20
    Reported Apr 28
    		$1.56$1.36+14.71%Beat+28.9%
    Dec 19
    Reported Jan 29
    		$1.32$1.31+0.76%Beat+5.6%
    Sep 19
    Reported Oct 22
    		$1.41$1.35+4.44%Beat+6.8%
    Jun 19
    Reported Jul 18
    		$1.34$1.23+8.94%Beat+3.9%
    Mar 19
    Reported Apr 24
    		$1.21$1.21+0.00%Beat-5.5%
    Dec 18
    Reported Jan 30
    		$1.25$1.30-3.85%Miss+3.3%
    Sep 18
    Reported Oct 18
    		$1.32$1.34-1.49%Miss+2.3%
    Jun 18
    Reported Jul 18
    		$1.29$1.28+0.78%Beat+5.7%
    Mar 18
    Reported Apr 19
    		$1.28$1.27+0.79%Beat+13.3%
    Dec 17
    Reported Jan 24
    		$1.21$1.17+3.42%Beat+8.0%
    Sep 17
    Reported Oct 24
    		$1.29$1.24+4.03%Beat+4.9%
    Jun 17
    Reported Jul 18
    		$1.22$1.17+4.27%Beat-
    Mar 17
    Reported Apr 25
    		$1.13$1.10+2.73%Beat-
    Dec 16
    Reported Jan 25
    		$1.12$1.10+1.82%Beat-
    Sep 16
    Reported Oct 25
    		$1.23$1.19+3.36%Beat-

    Dividends

    Dividend Metrics

    Yield3.14%
    Annual/Share$4.77
    Payout Ratio49.68%
    Frequency1
    Pay MonthsMar

    Growth

    3Y CAGR+6.30%
    5Y CAGR+5.28%
    View NVS's full dividend history

    Key Metrics

    Valuation
    P/E Ratio18.23EV/EBITDA14.94x
    Price/FCF18.40xFCF Yield5.44%
    Profitability
    Profit Margin22.50%Operating Margin34.60%
    ROE30.30%ROIC15.68%
    Financial Health
    Debt/Equity1.13xInterest Coverage12.17x
    Current Ratio0.86xQuick Ratio0.67x
    Trading Statistics
    Beta0.49Avg Volume1.39M
    52-Week High$165.4352-Week Low$117.98

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$156.60
    SMA 20$155.13
    SMA 50$154.90
    SMA 200$147.40
    EMA 10$155.33
    EMA 20$155.34
    EMA 50$154.36
    EMA 200$146.45

    MACD

    Line: 0.19Signal: 0.55Hist: -0.36

    ADX

    ADX: 12.4+DI: 24.0-DI: 27.6

    Aroon & PSAR

    Aroon Up68.0
    Aroon Down56.0
    PSAR$150.84

    Bollinger Bands

    Upper Band$160.71
    Lower Band$149.54
    %B Position720%(Upper)
    Band Width0.23

    RSI (14-Day)

    Neutral
    44.0

    Momentum Oscillators

    Stoch %K37.7
    Stoch %D53.9
    Williams %R-74.7
    ROC (10d)0.1%
    Momentum0.09
    CCI (20d)-92.4
    MFI (14d)35.9

    Volatility Measures

    ATR (14d)$2.87(1.9%)
    StdDev (20d)2.79
    Hist Vol23.8%(Moderate)

    Volume Flow

    VWAP$152.16
    OBV31.9M
    AD Line-997.7M
    CMF (20d)-0.071

    Volume Metrics

    Avg Vol (20d)1.4M
    Vol Ratio0.9x
    VWMA (20d)$155.03

    Pivot Points

    R3$156.46
    R2$155.51
    R1$154.66
    Pivot Point$153.72
    S1$152.87
    S2$151.92
    S3$151.07

    Advanced Oscillators

    TSI1.51
    Ultimate Osc47.0
    KST5.76

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$14.42B$13.52B$13.33B$14.36B$14.36B$14.84B$13.62B$13.56B$13.17B$12.87B$12.12B$11.78B
    Cost of Revenue$3.68B$3.46B$3.54B$3.54B$3.54B$3.32B$3.23B$3.32B$3.23B$3.17B$3.10B$3.02B
    Gross Profit$10.74B$10.06B$9.79B$10.82B$10.82B$11.51B$10.39B$10.23B$9.94B$9.70B$9.02B$8.75B
    Operating Expenses$6.00B$5.83B$6.27B$6.32B$6.32B$6.65B$5.73B$6.70B$6.31B$5.68B$5.65B$6.17B
    R&D$2.76B$2.74B$2.84B$2.94B$2.94B$2.73B$2.37B$2.84B$2.39B$2.37B$2.42B$2.57B
    SG&A$3.24B$3.14B$3.44B$3.31B$3.31B$3.44B$3.06B$3.50B$3.13B$3.09B$2.84B$3.44B
    Operating Income$4.74B$4.24B$3.52B$4.50B$4.50B$4.86B$4.66B$3.53B$3.63B$4.01B$3.37B$2.58B
    Interest Income$0$0$306.00M$285.00M$0$292.00M$273.00M$200.00M$0$0$6.00M$0
    Interest Expense$462.32M$343.00M$303.98M$281.00M$281.00M$293.64M$270.22M$273.05M$266.88M$245.62M$219.74M$238.87M
    Income Before Tax$4.27B$3.84B$3.22B$4.20B$4.20B$4.53B$4.41B$3.29B$3.38B$3.84B$3.13B$2.38B
    Income Tax Expense$1.01B$683.00M$813.94M$266.00M$266.00M$507.00M$798.00M$465.00M$200.00M$595.00M$441.00M$-261,000,000
    Net Income$3.27B$3.16B$2.41B$3.93B$3.93B$4.04B$3.61B$2.82B$3.19B$3.25B$2.69B$8.48B
    EBITDA$5.94B$5.41B$5.07B$5.84B$5.84B$6.08B$5.83B$5.19B$5.61B$5.25B$4.66B$4.18B
    EBIT$4.74B$4.18B$3.52B$4.48B$4.48B$4.82B$4.68B$3.56B$3.65B$4.09B$3.35B$2.59B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    When the Old Playbook Fails: Building a Real Defensive Portfolio for the 2026 Oil Shock

    The S&P 500 is already 5% off its January peak. A 10% correction only needs another 5.3% lower and current models put that at 72% probability before year-end 2026. This correction is oil-driven, not recession-driven. That distinction changes which defensives actually work. Classic staples have underperformed energy on the worst selloff days this cycle. Regulated utilities have a structural advantage in an oil-shock correction: their input cost recovery is set by regulators, not spot markets. Two utilities with Safety Scores above 92 are highlighted in the full analysis The basket pairs a defensive cash-flow core with one gold mining position screened for balance sheet quality: Altman Z-Score above 7, Piotroski F-Score of 8, and near-zero debt. Geopolitical hedges are not all equal. Correction thresholds that matter: 6,280 (10%), 5,931 (15%), and 5,582 (20%). The full report includes a trigger matrix for each level, with the market conditions that would raise or lower each probability.

    Unknown Author
    •
    3/15/26
    •
    432
    market correction
    defensive stocks
    Also mentions:
    NVS
    PEG
    MDT
    AEM

    Incyte’s Earnings: Strong Growth Amid Market Overlook

    INCY generates $1.17B annual FCF with 93% gross margins and zero leverage, yet trades at 15.6x earnings. Reverse-DCF implies ~0% growth priced in. Quality Score 100/100 with ROIC 25.4%, Piotroski 8/9, interest coverage 702x, and $3.6B cash. This is fortress-grade biotech. Q4 revenue crushed estimates by 11% ($1.51B vs $1.35B). Full year $5.14B, up 21%. Core business ex-Jakafi grew 53% to $1.26B. Replacement revenue already $1.26B and guided to grow 30% in 2026. Management targets $3-4B core ex-Jakafi by 2030, turning the patent cliff into a slope. Post-earnings pullback breached first buy zone. Three tranches: current levels near $100, $96-$99 (channel support), $88-$92 (200-day defense). Blended fair value ~$155 implies ~55% upside. Four product launches on deck late 2026/early 2027: Jakafi XR, Opzelura moderate AD, Monjuvi sBLA, Povorcitinib.

    Unknown Author
    •
    2/11/26
    •
    129
    Biotech
    Healthcare Stocks
    Also mentions:
    NVS
    LLY
    REGN
    GILD

    Government Contracts

    Gov Obligations (TTM)
    $29.09M
    Gov Obligations / Revenue
    0.1%
    Obligations YoY
    42.0%
    Active Awards
    78
    New Awards (TTM)
    50
    Avg Remaining Term
    3.2 mo

    Top agency: Department of Veterans Affairs at 85.1% of trailing twelve month obligations across 3 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C24826F0082Department of Veterans AffairsDepartment of Veterans Affairs$4.73MFeb 24, 2026
    36C25726N0205Department of Veterans AffairsDepartment of Veterans Affairs$4.16MFeb 7, 2026
    36C26126F0007Department of Veterans AffairsDepartment of Veterans Affairs$3.99MOct 1, 2025
    36C26226N0112Department of Veterans AffairsDepartment of Veterans Affairs$3.91MNov 1, 2025
    W81K0025FA195Department of DefenseDepartment of the Army$3.23MOct 1, 2025
    36C24926N0263Department of Veterans AffairsDepartment of Veterans Affairs$2.91MDec 20, 2025
    36C25026N0310Department of Veterans AffairsDepartment of Veterans Affairs$2.42MFeb 1, 2026
    36C24426F0063Department of Veterans AffairsDepartment of Veterans Affairs$1.98MJan 1, 2026
    36C26126F0017Department of Veterans AffairsDepartment of Veterans Affairs$1.63MOct 1, 2025
    36C25526N0132Department of Veterans AffairsDepartment of Veterans Affairs$1.20MFeb 17, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Novartis says MS pill succeeds in two large studies

    Novartis announced that its investigational multiple sclerosis drug, remibrutinib, succeeded in two Phase 3 trials, outperforming Aubagio in reducing relapse rates and brain lesions without causing liver-related side effects, a common issue with other BTK inhibitors. This success has led to a rise in company shares and positions remibrutinib, already approved for chronic skin hives, for potential significant sales in MS and other neurological/inflammatory conditions, with analysts projecting multi-billion dollar peak annual sales. The company plans to share detailed results with health regulators soon.

    BioPharma Dive•9/1/26•
    Bullish

    Delhi High Court Directs BDR To Seek Prior Approval Before 'Dabrafenib' Launch In Novartis Patent Suit

    The Delhi High Court has ordered BDR Pharmaceuticals International Private Limited to obtain prior approval from the court before commercially manufacturing or launching 'Dabrafenib'. This directive was issued during a patent infringement dispute initiated by Novartis AG, which sought to prevent apprehended infringement. Novartis's concerns arose from an RTI response indicating BDR had been granted licenses for Dabrafenib manufacturing, though BDR clarified these were for examination and testing, not commercial use.

    LiveLawBiz•8/26/26•
    Somewhat-Bullish

    Novartis stock trades steadily as Q2 2026 earnings growth supports outlook

    Novartis stock is trading steadily, supported by strong Q2 2026 revenue and earnings per share growth compared to Q2 2025. This performance, driven by key pharmaceutical franchises and new launches, reinforces investor confidence and provides a stronger earnings base for the second half of 2026. The company's dual listing on the SIX Swiss Exchange and as an American Depositary Receipt (ADR) in New York offers global investors flexible access to its shares.

    Ad-hoc-news.de•8/26/26•
    Bullish

    Novartis AG : Gets a Buy rating from Deutsche Bank

    Deutsche Bank has issued a "Buy" rating for Novartis AG, maintaining an unchanged target price of CHF 140. This news highlights a positive analyst outlook for the pharmaceutical company, reinforcing investor confidence. Novartis AG is a global leader in pharmaceuticals, focusing on oncology, immunology, and cardiovascular diseases.

    www.marketscreener.com•8/25/26•
    Bullish

    Novartis stock holds firm after Q2 2026 growth and dual listing support

    Novartis stock remains stable in late August 2026, supported by strong Q2 2026 revenue growth and a robust US ADR price. The company's performance, including improved earnings per share and ongoing pipeline development, reinforces its investment case despite market fluctuations and patent-cliff dynamics. Its dual listing in Zurich and New York provides liquidity and currency diversification, with the ADR trading at a premium, reflecting investor confidence in future execution and shareholder returns.

    Ad-hoc-news.de•8/25/26•
    Bullish

    Frequently Asked Questions About NVS

    What is NVS's current dividend yield?
    Novartis AG ADR (NVS) has a current dividend yield of 3.14%.
    Does NVS pay dividends?
    Yes, Novartis AG ADR pays dividends with a current yield of 3.14%.
    What is NVS's P/E ratio?
    Novartis AG ADR has a price-to-earnings (P/E) ratio of 18.23.
    What is NVS's market cap?
    Novartis AG ADR (NVS) has a market capitalization of $289.02B with a current stock price of $152.06.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In